Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats

Brain Research

Volumn 1098, Issue 1, 2006, Pages 71-78

  Alfinito, Peter D ^a   Huselton, Christine ^a   Chen, Xiaohong ^a   Deecher, Darlene C ^a  

^a PFIZER INC   (United States)

Author keywords

Blood brain barrier; Depression; Hot flush; Hypothalamus; Microdialysis; Non hormonal

Indexed keywords

DESVENLAFAXINE; DOPAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG PENETRATION; FEMALE; HALF LIFE TIME; HYPOTHALAMUS; MALE; MENOPAUSE; MICRODIALYSIS; NONHUMAN; OVARIECTOMY; PREOPTIC AREA; PRIORITY JOURNAL; RAT; RAT STRAIN;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BRAIN CHEMISTRY; CYCLOHEXANOLS; DOPAMINE; FEMALE; MICRODIALYSIS; NOREPINEPHRINE; OVARIECTOMY; PREOPTIC AREA; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOTAXIC TECHNIQUES;

DAPHNE VIRUS S;

EID: 33747781409     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.04.057     Document Type: Article

References (29)

1. Anakk S., Ku C.Y., Vore M., and Strobel H.W. Insights into gender bias: rat cytochrome P450 3A9. J. Pharmacol. Exp. Ther. 305 (2003) 703-709
2. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J. Psychopharmacol. 16 (2002) 297-304
3. Boulant J.A. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clin. Infect. Dis. 31 (2000) S157-S161
4. Cosmi, S., Maswood, N., Alfinito, P., Huselton, C., Beyer, C., Deecher, D., 2005. Desvenlafaxine succinate is a brain-penetrable serotonin and norepinephrine reuptake inhibitor: pharmacokinetic and neurochemical studies in Sprague-Dawley rats, 2005 Abstract Viewer/Itinerary Planner Washington, DC: Soc. Neurosci. (CD-ROM).
5. David D.J.P., Bourin M., Jego G., Przybylski C., Jolliet P., and Gardier A.M. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br. J. Pharmacol. 140 (2003) 1128-1136
6. 1A receptor antagonism. Neuropharmacology 38 (1999) 1153-1163
7. Deecher, D.C., Beyer, C.E., Johnston, G., Bray, J., Shah, S., Abou-Gharbia, M., Andree, T.H., in press. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther.
8. Engelman E.A., Perry K.W., Mayle D.A., and Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 12 (1995) 287-295
9. Gardier A.M., Malagie I., Trillat A.C., Jacquot C., and Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol. 10 (1996) 16-27
10. Gur E., Dremencov E., Lerer B., and Newman M.E. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol. 372 (1999) 17-24
11. 1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur. J. Clin. Pharmacol. 58 (2002) 621-628
12. Klamerus K.J., Parker V.D., Rudolph R.L., Derivan A.T., and Chiang S.T. Effects of age and gender on venlafaxine and o-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 16 (1996) 915-923
13. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., and Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27 (2002) 949-959
14. Kudo N., Katakura M., Sato Y., and Kawashima Y. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem.-Biol. Interact. 139 (2002) 301-316
15. Mariappan P., Ballantyne Z., N'Dow J.M., and Alhasso A.A. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst. Rev. (2005) (Issue 3. Art. No.: CD004742. doi:10.1002/14651858.CD004742.pub2)
16. 1A receptors. J. Psychopharmacol. 16 (2002) 253-260
17. Moy L.Y., Zeevalk G.D., and Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem. 74 (2000) 1656-1665
18. Muth E.A., Moyer J.A., Haskins J.T., Andree T.H., and Husbands G.E. Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23 (1991) 191-199
19. Öztas B., and Kaya M. Influence of orchidectomy and ovariectomy on the blood-brain barrier permeability during bicuculline-induced seizures. Horm. Metab. Res. 30 (1998) 500-503
20. Öztas B., Camurcu S., and Kaya M. Influence of sex on the blood brain barrier permeability during bicuculline-induced seizures. Int. J. Neurosci. 65 (1992) 131-139
21. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
22. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. 37 (2003) 1561-1565
23. Schober C.E., and Ansani N.T. Venlafaxine hydrochloride for the treatment of hot flashes. Ann. Pharmacother. 37 (2003) 1703-1707
24. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 121 (1997) 941-946
25. Shimizu N., Take S., Hori T., and Oomura Y. In vivo measurement of hypothalamic serotonin release by intracerebral microdialysis: significant enhancement by immobilization stress in rats. Brain Res. Bull. 28 (1992) 727-734
26. Sonsalla P.K., Youngster S.K., Kindt M.V., and Heikkila R.E. Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J. Pharmacol. Exp. Ther. 242 (1987) 850-857
27. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther. 24 (1999) 339-346
28. Watanabe M., Tanaka M., Tateishi T., Nakura H., Kumai T., and Kobayashi S. Effects of the estrous cycle and the gender difference on hepatic drug-metabolising enzyme activities. Pharmacol. Res. 35 (1997) 477-480
29. Zeevalk G.D., Manzino L., Hoppe J., and Sonsalla P. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism. Eur. J. Pharmacol. 320 (1997) 111-119